China Pharma, Biotech Firms Could Lift Guidance After Strong Earnings -- Market Talk

Dow Jones

3 hours ago

1005 GMT - Chinese pharma and biotech firms are poised to deliver solid 2H results, driven by stronger-than-expected innovative drug sales and licensing income, Citi analysts say in a note. Fosun Pharma's revenue could beat forecasts due to its business development deal with Pfizer, while Hansoh Pharma's results are expected to meet expectations as innovative drug sales track guidance. Most contract development and manufacturing organizations have issued positive profit alerts, and further guidance upgrades are likely. Specifically, WuXi AppTec's launch of its orforglipron drug may lift its revenue and profit outlook. Citi has a positive catalyst watch on names that could deliver earnings beats and guidance raises, including United Imaging, Pharmaron and Yifeng. (jason.chau@wsj.com)

(END) Dow Jones Newswires

February 24, 2026 05:05 ET (10:05 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2613794736"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613794736\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613794736?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 18:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613794736","market":"nz","top_or_hot":-1,"title":"China Pharma, Biotech Firms Could Lift Guidance After Strong Earnings -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1005 GMT - Chinese pharma and biotech firms are poised to deliver solid 2H results, driven by stronger-than-expected innovative drug sales and licensing income, Citi analysts say in a note. Fosun Pharma's revenue could beat forecasts due to its business development deal with Pfizer, while Hansoh Pharma's results are expected to meet expectations as innovative drug sales track guidance. Most contract development and manufacturing organizations have issued positive profit alerts, and further guidance upgrades are likely. Specifically, WuXi AppTec's launch of its orforglipron drug may lift its revenue and profit outlook. Citi has a positive catalyst watch on names that could deliver earnings beats and guidance raises, including United Imaging, Pharmaron and Yifeng. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2026 05:05 ET (10:05 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Pharma, Biotech Firms Could Lift Guidance After Strong Earnings -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Pharma, Biotech Firms Could Lift Guidance After Strong Earnings -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-24 18:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1005 GMT - Chinese pharma and biotech firms are poised to deliver solid 2H results, driven by stronger-than-expected innovative drug sales and licensing income, Citi analysts say in a note. Fosun Pharma's revenue could beat forecasts due to its business development deal with Pfizer, while Hansoh Pharma's results are expected to meet expectations as innovative drug sales track guidance. Most contract development and manufacturing organizations have issued positive profit alerts, and further guidance upgrades are likely. Specifically, WuXi AppTec's launch of its orforglipron drug may lift its revenue and profit outlook. Citi has a positive catalyst watch on names that could deliver earnings beats and guidance raises, including United Imaging, Pharmaron and Yifeng. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2026 05:05 ET (10:05 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2613794736","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613794736","pubTimestamp":1771927500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1005 GMT - Chinese pharma and biotech firms are poised to deliver solid 2H results, driven by stronger-than-expected innovative drug sales and licensing income, Citi analysts say in a note. Fosun Pharma's revenue could beat forecasts due to its business development deal with Pfizer, while Hansoh Pharma's results are expected to meet expectations as innovative drug sales track guidance. Most contract development and manufacturing organizations have issued positive profit alerts, and further guidance upgrades are likely. Specifically, WuXi AppTec's launch of its orforglipron drug may lift its revenue and profit outlook. Citi has a positive catalyst watch on names that could deliver earnings beats and guidance raises, including United Imaging, Pharmaron and Yifeng. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","CPHI":"惠普森医药"},"translate_title":"中国制药和生物技术公司在强劲盈利后可能会上调指引——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPHI":1.5,"LABU":1.5},"content_text":"1005 GMT - Chinese pharma and biotech firms are poised to deliver solid 2H results, driven by stronger-than-expected innovative drug sales and licensing income, Citi analysts say in a note. Fosun Pharma's revenue could beat forecasts due to its business development deal with Pfizer, while Hansoh Pharma's results are expected to meet expectations as innovative drug sales track guidance. Most contract development and manufacturing organizations have issued positive profit alerts, and further guidance upgrades are likely. Specifically, WuXi AppTec's launch of its orforglipron drug may lift its revenue and profit outlook. Citi has a positive catalyst watch on names that could deliver earnings beats and guidance raises, including United Imaging, Pharmaron and Yifeng. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2026 05:05 ET (10:05 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}